LLY News

Novo Nordisk's ESSENCE trial of semaglutide 2.4 mg shows significant improvements in liver fibrosis and steatohepatitis outcomes, with regulatory filings planned for 2025.

Compounding weight loss drugs, which are similar to brand-name medications such as Ozempic and Mounjaro, will be banned in Australia.

Nestlé SA launches Vital Pursuit, a new food line tailored for GLP-1 weight loss medication users, featuring protein, fiber, and essential nutrients. Available Q4 nationwide.

Eli Lilly's diabetes drug tirzepatide receives approval in China, intensifying competition with Novo Nordisk's Ozempic. This move signals a significant expansion in the Asian market, where GLP-1 agonists are poised to drive a $2 billion market by 2030.

Eli Lilly phase 3 trials reveal once-weekly insulin efsitora as a non-inferior alternative to daily basal insulins for type 2 diabetes.

A whale with a lot of money to spend has taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 15 strange trades.

Eli Lilly (NYSE:LLY) has observed the following analyst ratings within the last quarter:

Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 9.8% on an annualized basis producing an average annual return of 21.54%. Currently, Eli Lilly has a market capitalization of $276.68 billion.

Benzinga's options scanner just detected over 16 options trades for Eli Lilly (NYSE:LLY) summing a total amount of $701,114. At the same time, our algo caught 4 for a total amount of 146,845.

Eli Lilly and Company's (NYSE:LLY) short percent of float has fallen 12.05% since its last report. The company recently reported that it has 5.79 million shares sold short, which is 0.73% of all regular shares that are available for trading.

Eli Lilly (NYSE:LLY) reported its Q1 earnings results on Thursday, April 28, 2022 at 06:25 AM. Here's what investors need to know about the announcement.